Suda T. Targeting therapy for hepatocellular carcinoma by delivering microRNAs as exosomal cargo. World J Gastroenterol 2024; 30(17): 2369-2370 [PMID: 38813056 DOI: 10.3748/wjg.v30.i17.2369]
Corresponding Author of This Article
Takeshi Suda, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, 4132 Urasa, Minami Uonuma 949-7302, Niigata, Japan. tspitt@med.niigata-u.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 7, 2024; 30(17): 2369-2370 Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2369
Targeting therapy for hepatocellular carcinoma by delivering microRNAs as exosomal cargo
Takeshi Suda
Takeshi Suda, Department of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minami Uonuma 949-7302, Niigata, Japan
Author contributions: Suda T read the review article by Wang et al and wrote this entire letter to the editor.
Conflict-of-interest statement: The author declares he has no conflicts of interest in relation to this letter.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Takeshi Suda, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, 4132 Urasa, Minami Uonuma 949-7302, Niigata, Japan. tspitt@med.niigata-u.ac.jp
Received: January 20, 2024 Revised: March 6, 2024 Accepted: April 11, 2024 Published online: May 7, 2024 Processing time: 106 Days and 3.2 Hours
Abstract
Exosomes, the smallest extracellular vesicles, have gained significant attention as key mediators in intercellular communication, influencing both physiological and pathological processes, particularly in cancer progression. A recent review article by Wang et al was published in a timely manner to stimulate future research and facilitate practical developments for targeted treatment of hepatocellular carcinoma using exosomes, with a focus on the origin from which exosomes derive. If information about the mechanisms for delivering exosomes to specific cells is incorporated, the concept of targeted therapy for hepatocellular carcinoma using exosomes could be more comprehensively understood.
Core Tip: Wang et al thoroughly explored the functions and biomedical significance of exosomal microRNAs transferred by both parenchymal and nonparenchymal cells in the framework of potential therapeutic targets for hepatocellular carcinoma. This review aimed to do more than just summarize the role of microRNAs in hepatocarcinogenesis. It also sought to illuminate the process of cellular communication using exosomal microRNA cargo. Therefore, it would be beneficial for the review to include information on how this cargo is delivered to target cells.
